Login / Signup

Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans.

Lília EspadaAlexander DakhovnikPrerana ChaudhariAsya MartirosyanLaura MiekTetiana PoliezhaievaYvonne SchaubAshish NairNadia DöringNorman RahnisOliver WerzAndreas KoeberleJoanna KirkpatrickAlessandro OriMaria A Ermolaeva
Published in: Nature metabolism (2020)
Current clinical trials are testing the life-extending benefits of the diabetes drug metformin in healthy individuals without diabetes. However, the metabolic response of a non-diabetic cohort to metformin treatment has not been studied. Here, we show in C. elegans and human primary cells that metformin shortens lifespan when provided in late life, contrary to its positive effects in young organisms. We find that metformin exacerbates ageing-associated mitochondrial dysfunction, causing respiratory failure. Age-related failure to induce glycolysis and activate the dietary-restriction-like mobilization of lipid reserves in response to metformin result in lethal ATP exhaustion in metformin-treated aged worms and late-passage human cells, which can be rescued by ectopic stabilization of cellular ATP content. Metformin toxicity is alleviated in worms harbouring disruptions in insulin-receptor signalling, which show enhanced resilience to mitochondrial distortions at old age. Together, our data show that metformin induces deleterious changes of conserved metabolic pathways in late life, which could bring into question its benefits for older individuals without diabetes.
Keyphrases